Trial Profile
Phase I trial of SAGE 689 in healthy volunteers
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2021
Price :
$35
*
At a glance
- Drugs SAGE 689 (Primary)
- Indications Status epilepticus
- Focus Adverse reactions
- Sponsors Sage Therapeutics
- 24 Feb 2021 According to a Sage Therapeutics media release, the company expects to complete this study in late 2021.
- 07 Jan 2021 According to a Sage Therapeutics media release, the company expects to complete this study in 2021.
- 12 Nov 2019 According to a Sage Therapeutics media release, The IND for SAGE-689 was cleared by the FDA and the Company expects to commence dosing in a Phase 1 clinical trial in healthy volunteers in 2020.